ABO-incompatible liver transplantation: a new therapeutic option for patients with acute liver failure in Chile.
Different ways have been suggested to expand donor numbers for liver transplantation. Transplantation using ABO-incompatible hepatic grafts has recently been a controversial issue due to the high risk of hyperacute rejection mediated by preformed anti-ABO antibodies. We report three patients with acute liver failure who were transplanted with ABO-incompatible livers: A to O in two patients and A to B in one case. We used pre- and posttransplant total plasma exchange, splenectomy, and triple immunosuppression. All three patients are alive; one graft was lost, probably secondary to thrombotic microangiopathy with low isohemagglutinin titers of 1:8. One patient developed acute cellular rejection that was reversed with a bolus of methylprednisolone. No antibody-mediated rejection occurred. Financial and infectious considerations have to be considered. In our series, the final liver transplantation cost was higher than average for acute liver failure. Plasmapheresis has the highest cost of all the additional procedures. ABO-incompatible liver transplantation, because of the splenectomy it requires, has been associated with more infections due to encapsulated organisms. However, with splenectomy in our three patients, none had infections due to these bacteria. In our country, we do not consider ABO-incompatible liver transplantation as a first-line option, except for highly selected patients.
Uribe
M
M
Liver Transplantation Program, Clínica Las Condes-Hospital Luis Calvo MacKenna, Santiago, Chile. muribe@manquehue.net
Buckel
E
E
Ferrario
M
M
Segovia
R
R
González
G
G
Hunter
B
B
Godoy
J
J
Berwart
F
F
Brahm
J
J
Silva
G
G
Cavallieri
S
S
Calabrán
L
L
Santander
M T
MT
Herzog
C
C
D000017:ABO Blood-Group System; D000328:Adult; D001787:Blood Group Incompatibility; D002675:Child, Preschool; D002677:Chile; D005260:Female; D006801:Humans; D017114:Liver Failure, Acute / Q000601:surgery*; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D016896:Treatment Outcome
D000017:ABO Blood-Group System